

Date: 13th February 2025

To, Listing Compliance Department, National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai-400051

NSE Symbol: Madhavbaug

Sub: Intimation under Regulation 32 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Madam,

Pursuant to Regulation 32 of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No CIR/CFD/CMDl/162 /2019 dated 24th December 2019, we hereby confirm that:

- a) there was no deviation in the utilization of proceeds of Preferential Issue of Share Warrants from the objects as stated in explanatory statement to the notice of General Meeting held on 24th April, 2023 and 05th August, 2023;
- b) there has been no variation in the use of proceeds Preferential Issue of Shares Warrants from the objects as stated in explanatory statement to the notice of General Meeting held on 24^{th} April, 2023 and 05^{th} August, 2023.

The statement of deviation as enclosed herewith as "Annexure -A", has also been reviewed by the Audit Committee at its Meeting held on 13th February, 2025 as required under Regulation 32(3) of the SEBI (Listing Obligations and Disclosure Requirement) Regulations. 2015.

The aforesaid information shall also be disclosed on the website of the company.

We would request you to take the above intimation on records.

For, Vaidya Sane Ayurved Laboratories Limited

Vidyut Bipin Ghag Whole-Time Director DIN: 09299252

VAIDYA SANE AYURVED LABORATORIES LIMITED



ANNEXURE-A

Statement of Deviation/ Variation in utilisation of Funds Raised Statement - Preferential Issue

Name of listed entity	Vaidya Sane Ayurved Laboratories Limited
Mode of Fund Raising	Preferential Issues by way of issue of Convertible Share Warrants Preferential Issues by way of issue of Convertible Share Warrants
Date of Raising Funds	1. 27 th May 2023 - pursuant to approval of shareholders on 24 th April 2023, Allotment of 5,00,000 Share warrants convertible into Equity Shares on preferential basis to Promoter and Promoter Group
	2. 14th August 2023 - pursuant to approval of shareholders on 05th August, 2023, Allotment of 16,34,400 Share warrants convertible into Equity Shares on preferential basis to Non-Promoter Group
Amount Raised	1. Preferential Issues by way of issue of Convertible Share Warrants Rs. 2,76,68,750 (being 25% of the Issue Price of the Warrants) 2. Preferential Issues by way of issue of Convertible Share Warrants Rs. 10,66,44,600 (being 25% of the Issue Price of the Warrants)
Report filed for Half yearly ended	31 th December 2024
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised If yes, whether the same is pursuant to	NO Fund raised was kept in separate fund raising bank account. Not Applicable
change in terms of a contract or objects, which was approved by the Shareholders	

VAIDYA SANE AYURVED LABORATORIES LIMITED



							Multidisciplinary Cardiac Ca	re Clinics & Hospitals		
If Yes, Date of shareholder Approval					pplicab	le				
Explanation for the Deviation / Variation					Not Applicable					
Comments of the Audit Committee after review					None- reviewed by the Audit Committee at its Meeting held on 13th February, 2025					
Comments	Comments of the auditors, if any					None				
Objects for which funds have been raised and where there has been a deviation, in the following table			1. Preferential Issues by way of issue of Convertible Share Warrants The purpose of the issue of Share warrants convertible into equity shares are to meet the working capital requirements, General corporate purpose and such other purpose as the Board of Directors may decide. 2. Preferential Issues by way of issue of Convertible Share Warrants The purpose of the issue of Share warrants convertible into equity shares are to augment funding needs of the Company viz., to meet general corporate purpose, to support the future growth plans of the Company.							
Original Object	Modified Object , if any	Original Allocation	Modif Alloca if any	ntion,	Funds utilize		Amount of Deviation/Variation for the half yearly according to applicable object	Remarks, if any		
Not Applicable										

For, Vaidya Sane Ayurved Laboratories Limited

Vidyut Bipin Ghag Whole-Time Director DIN: 09299252

VAIDYA SANE AYURVED LABORATORIES LIMITED